Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study
| dc.creator | Mahil, Satveer K. | |
| dc.creator | Dand, Nick | |
| dc.creator | Mason, Kayleigh J. | |
| dc.creator | Yiu, Zenas ZN. | |
| dc.creator | Tsakok, Teresa | |
| dc.creator | Meynell, Freya | |
| dc.creator | Coker, Bola | |
| dc.creator | McAteer, Helen | |
| dc.creator | Moorhead, Lucy | |
| dc.creator | Mackenzie, Teena | |
| dc.creator | Rossi, Maria Teresa | |
| dc.creator | Rivera, Raquel | |
| dc.creator | Mahe, Emmanuel | |
| dc.creator | Carugno, Andrea | |
| dc.creator | Magnano, Michela | |
| dc.creator | Rech, Giulia | |
| dc.creator | Balogh, Esther A. | |
| dc.creator | Feldman, Steven R. | |
| dc.creator | Cruz, Claudia De La | |
| dc.creator | Choon, Siew Eng | |
| dc.creator | Naldi, Luigi | |
| dc.creator | Lambert, Jo | |
| dc.creator | Spuls, Phyllis | |
| dc.creator | Jullien, Denis | |
| dc.creator | Bachelez, Hervé | |
| dc.creator | McMahon, Devon E. | |
| dc.creator | Freeman, Esther E. | |
| dc.creator | Gisondi, Paolo | |
| dc.creator | Puig, Luis | |
| dc.creator | Warren, Richard B. | |
| dc.creator | Meglio, Paola Di | |
| dc.creator | Langan, Sinéad M. | |
| dc.creator | Capon, Francesca | |
| dc.creator | Griffiths, Christopher EM. | |
| dc.creator | FMedSci, MD | |
| dc.creator | Barker, Jonathan N. | |
| dc.creator | Smith, Catherine H. | |
| dc.date.accessioned | 2020-10-22T17:45:26Z | |
| dc.date.available | 2020-10-22T17:45:26Z | |
| dc.date.created | 2020 | |
| dc.description.abstract | Background: The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited. Objective: Characterize the course of COVID-19 in psoriasis and identify factors associated with hospitalization. Methods: Clinicians reported psoriasis patients with confirmed/suspected COVID-19 via an international registry, PsoProtect. Multiple logistic regression assessed the association between clinical/demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviours. Results: Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% a non-biologic and 10% no systemic treatment for psoriasis. 348 (93%) fully recovered from COVID-19, 77 (21%) were hospitalized and nine (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted OR 1.59 per 10 years, 95% CI 1.19-2.13), male sex (OR 2.51, 95% CI 1.23-5.12), non-white ethnicity (OR 3.15, 95% CI 1.24- 8.03) and comorbid chronic lung disease (OR 3.87, 95% CI 1.52-9.83). Hospitalization was more frequent in patients using non-biologic systemic therapy than biologics (OR 2.84, 95% CI 1.31-6.18). No significant differences were found between biologic classes. Independent patient-reported data (n=1,626 across 48 countries) suggested lower levels of social isolation in individuals receiving non-biologic systemic therapy compared to biologics (OR 0.68, 95% CI 0.50-0.94). Conclusion: In this international moderate-severe psoriasis case series, biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding. Established risk factors (being older, male, non-white ethnicity, comorbidities) were associated with higher hospitalization rates. | spa |
| dc.format.extent | 34 páginas | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.identifier.doi | https://doi.org/10.1016/j.jaci.2020.10.007 | spa |
| dc.identifier.issn | 0091-6749 | spa |
| dc.identifier.other | https://doi.org/10.1016/j.jaci.2020.10.007 | spa |
| dc.identifier.uri | https://hdl.handle.net/20.500.12010/14764 | |
| dc.language.iso | eng | spa |
| dc.publisher | Journal of Allergy and Clinical Immunology | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.local | Abierto (Texto Completo) | spa |
| dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
| dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
| dc.subject | COVID-19 | spa |
| dc.subject | Hospitalization | spa |
| dc.subject | Psoriasis | spa |
| dc.subject | Risk factors | spa |
| dc.subject | Biologics | spa |
| dc.subject | Mmunosuppressants | spa |
| dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
| dc.subject.lemb | COVID-19 | spa |
| dc.subject.lemb | SARS-CoV-2 | spa |
| dc.subject.lemb | Coronavirus | spa |
| dc.title | Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.type.local | Artículo | spa |
Archivos
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 2.87 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción:
